Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial

G. L. Davis, L. A. Balart, Eugene R Schiff, K. Lindsay, H. C. Bodenheimer, R. P. Perrillo, W. Carey, I. M. Jacobson, J. Payne, J. L. Dienstag, D. H. Van Thiel, C. Tamburro, J. Lefkowitch, J. Albrecht, C. Meschievitz, T. J. Ortego, A. Gibas

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To assess the efficacy of therapy with the antiviral agent interferon in chronic hepatitis C (non-A, non-B hepatitis), we randomly assigned 166 chronic hepatitis C patients to treatment with either 3 million or 1 million units of recombinant interferon alfa-2b three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after 6 months of interferon therapy was 46% in patients treated with 3 million units of interferon (p < 0.001) and 28% in those treated with 1 million units (p < 0.02), but only 8% in untreated patients. Serum alanine aminotransferase levels became completely normal in 22 of the 26 patients (85%) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56%) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histological improvement because of the regression of lobular and periportal inflammation. Relapse within 6 months after the completion of treatment occurred in 51% of the patients treated with 3 million units of interferon and 44% of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.

Original languageEnglish
JournalJournal of Hepatology
Volume11
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 1990

Fingerprint

Chronic Hepatitis C
Interferons
Randomized Controlled Trials
interferon alfa-2b
Therapeutics
Alanine Transaminase
Recurrence
Withholding Treatment
Hepatitis C
Serum
Hepatitis
Antiviral Agents
Inflammation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial. / Davis, G. L.; Balart, L. A.; Schiff, Eugene R; Lindsay, K.; Bodenheimer, H. C.; Perrillo, R. P.; Carey, W.; Jacobson, I. M.; Payne, J.; Dienstag, J. L.; Van Thiel, D. H.; Tamburro, C.; Lefkowitch, J.; Albrecht, J.; Meschievitz, C.; Ortego, T. J.; Gibas, A.

In: Journal of Hepatology, Vol. 11, No. SUPPL. 1, 01.01.1990.

Research output: Contribution to journalArticle

Davis, GL, Balart, LA, Schiff, ER, Lindsay, K, Bodenheimer, HC, Perrillo, RP, Carey, W, Jacobson, IM, Payne, J, Dienstag, JL, Van Thiel, DH, Tamburro, C, Lefkowitch, J, Albrecht, J, Meschievitz, C, Ortego, TJ & Gibas, A 1990, 'Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial', Journal of Hepatology, vol. 11, no. SUPPL. 1. https://doi.org/10.1016/0168-8278(90)90160-S
Davis, G. L. ; Balart, L. A. ; Schiff, Eugene R ; Lindsay, K. ; Bodenheimer, H. C. ; Perrillo, R. P. ; Carey, W. ; Jacobson, I. M. ; Payne, J. ; Dienstag, J. L. ; Van Thiel, D. H. ; Tamburro, C. ; Lefkowitch, J. ; Albrecht, J. ; Meschievitz, C. ; Ortego, T. J. ; Gibas, A. / Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial. In: Journal of Hepatology. 1990 ; Vol. 11, No. SUPPL. 1.
@article{9cab1dc3cbdc419082102f21cd6e0f90,
title = "Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial",
abstract = "To assess the efficacy of therapy with the antiviral agent interferon in chronic hepatitis C (non-A, non-B hepatitis), we randomly assigned 166 chronic hepatitis C patients to treatment with either 3 million or 1 million units of recombinant interferon alfa-2b three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after 6 months of interferon therapy was 46{\%} in patients treated with 3 million units of interferon (p < 0.001) and 28{\%} in those treated with 1 million units (p < 0.02), but only 8{\%} in untreated patients. Serum alanine aminotransferase levels became completely normal in 22 of the 26 patients (85{\%}) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56{\%}) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histological improvement because of the regression of lobular and periportal inflammation. Relapse within 6 months after the completion of treatment occurred in 51{\%} of the patients treated with 3 million units of interferon and 44{\%} of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.",
author = "Davis, {G. L.} and Balart, {L. A.} and Schiff, {Eugene R} and K. Lindsay and Bodenheimer, {H. C.} and Perrillo, {R. P.} and W. Carey and Jacobson, {I. M.} and J. Payne and Dienstag, {J. L.} and {Van Thiel}, {D. H.} and C. Tamburro and J. Lefkowitch and J. Albrecht and C. Meschievitz and Ortego, {T. J.} and A. Gibas",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/0168-8278(90)90160-S",
language = "English",
volume = "11",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial

AU - Davis, G. L.

AU - Balart, L. A.

AU - Schiff, Eugene R

AU - Lindsay, K.

AU - Bodenheimer, H. C.

AU - Perrillo, R. P.

AU - Carey, W.

AU - Jacobson, I. M.

AU - Payne, J.

AU - Dienstag, J. L.

AU - Van Thiel, D. H.

AU - Tamburro, C.

AU - Lefkowitch, J.

AU - Albrecht, J.

AU - Meschievitz, C.

AU - Ortego, T. J.

AU - Gibas, A.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - To assess the efficacy of therapy with the antiviral agent interferon in chronic hepatitis C (non-A, non-B hepatitis), we randomly assigned 166 chronic hepatitis C patients to treatment with either 3 million or 1 million units of recombinant interferon alfa-2b three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after 6 months of interferon therapy was 46% in patients treated with 3 million units of interferon (p < 0.001) and 28% in those treated with 1 million units (p < 0.02), but only 8% in untreated patients. Serum alanine aminotransferase levels became completely normal in 22 of the 26 patients (85%) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56%) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histological improvement because of the regression of lobular and periportal inflammation. Relapse within 6 months after the completion of treatment occurred in 51% of the patients treated with 3 million units of interferon and 44% of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.

AB - To assess the efficacy of therapy with the antiviral agent interferon in chronic hepatitis C (non-A, non-B hepatitis), we randomly assigned 166 chronic hepatitis C patients to treatment with either 3 million or 1 million units of recombinant interferon alfa-2b three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after 6 months of interferon therapy was 46% in patients treated with 3 million units of interferon (p < 0.001) and 28% in those treated with 1 million units (p < 0.02), but only 8% in untreated patients. Serum alanine aminotransferase levels became completely normal in 22 of the 26 patients (85%) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56%) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histological improvement because of the regression of lobular and periportal inflammation. Relapse within 6 months after the completion of treatment occurred in 51% of the patients treated with 3 million units of interferon and 44% of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.

UR - http://www.scopus.com/inward/record.url?scp=0025696946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025696946&partnerID=8YFLogxK

U2 - 10.1016/0168-8278(90)90160-S

DO - 10.1016/0168-8278(90)90160-S

M3 - Article

C2 - 2127785

AN - SCOPUS:0025696946

VL - 11

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - SUPPL. 1

ER -